Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), has received Fast Track designation from the US Food and Drug Administration (FDA). The designation follows the FDA’s clearance of an Investigational New Drug (IND) application for CTx001. GA is an advanced form of dry […] The post Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation appeared first on Pharmafile.

Continue reading →